Evidence Hub

Updated Perspectives on The Diagnosis, Management And Novel Drug Delivery Strategies For The Treatment Of Onychomycosis

Fiza Farheen, Hemant Kumar Yadav, Abhay Raizaday, Krati Dhakad

Journal of Pharmaceutical Negative Results, 2022

1 citation

Abstract

Onychomycosis is a common fungal infection of the nail unit worldwide which poses a therapeutic challenge for both practitioners & patients and can cause pain, difficulty with ambulation and psycho-social problems. The infection is frequently due to dermatophyte, while yeast and non-dermatophyte molds (NDMs) attributed especially in immunocompromised patients. NDMs and Candida species can be involved as primary or secondary pathogens. Candida onychomycosis (CO), most commonly caused by C. albicans and C. parapsilosis, is frequently associated with local or systemic immune disturbances. In the cases that the host immunity is severely affected, Candida acts as primary pathogen, while other diseases e.g., diabetes mellitus, malnutrition, and smoking serve as predisposing factors for candida to cause secondary infection. Approximately 90% of toenail and 75% of fingernail onychomycosis are caused by dermatophytes, notably Trichophyton mentagrophytes and Trichophyton rubrum. Clinical manifestations include discoloration of the nail, subungual hyperkeratosis, onycholysis, candida granuloma, paronychia and onychauxis. Microscopy and fungal culture are the gold standard techniques for onychomycosis diagnosis, but high false-negative rates have pushed for more accurate methods, such as histology and PCR. As NDMs are skin and laboratory contaminants, their presence as an infectious agent requires multiple confirmations and repeated sampling. The conventional treatment of onychomycosis…

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free